About 6,000 individuals participate in the U.S. transplant system as a living organ donor each year. Organ donation (most commonly a kidney or part of liver) by living individuals is a unique procedure, where healthy patients undergo a major surgical operation without any direct functional benefit to themselves. In this article, the authors explore how the ideal of informed consent guides education and evaluation for living organ donation. The authors posit that informed consent for living organ donation is a process. Though the steps in this process are partially standardized through national health policy, they can be improved through institutional structures at the local, transplant center-level. Effective structures and practices aimed at supporting and promoting comprehensive informed consent provide more opportunities for candidates to ask questions about the risks and benefits of living donation and to opt out voluntarily Additionally, these practices could enable new ways of measuring knowledge and improving the consent process.
Get full access to this article
View all access options for this article.
References
1.
A.Matas, J.Smith, and M.Skeanset al., “OPTN/SRTR 2012 Annual Data Report: Kidney,”American Journal of Transplantation14, no. S1 (2014): 11-44.
2.
Matas, supra note 1
3.
C. W.Lidz, P. S.Appelbaum, and A.Meisel, “Two Models of Implementing Informed Consent,”Archives of Internal Medicine148, no. 6 (1988):1385-1389.
4.
C.Thiessen, E.Gordon, P.Reese, and S.Kulkarni, “Development of a Donor — Centered Approach to Risk Assessment: Rebalancing Nonmaleficence and Autonomy,“American Journal of Transplantation15, no. 9 (2015): 2314-2323.
5.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, “The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research,” (Washington, D.C.: U.S. Government Printing Office, 1978); F. Delmonico, “A Report of the Amsterdam Forum on the Care of the Live Kidney Donor: Data and Medical Guidelines,” Transplantation 79, Suppl. 6 (2005): S53.
6.
T. L.Beauchamp and J. F.Childress, Principles of Biomedical Ethics (New York: Oxford University Press, 2001): at 104.
7.
M.Allen, P.Abt, and P.Reese, “What are the Harms of Refusing to Allow Living Kidney Donation? An Expanded View of Risks and Benefits,”American Journal of Transplantation14, no.3 (2014): 531-537.
8.
Organ Procurement and Transplantation Network, Policy 14.4 “Medical Evaluation Requirements for Living Donors,”January21, 2016 (2016): 181-187.
9.
M. B.Allen and P. P.Reese, “Transforming Living Kidney Donation with a Comprehensive Strategy,”PLoS Med, 13, no. 2 (2016): e1001948.
10.
E.Gordon, N.Beauvais, N.Theodoropoulos, et al., “The Challenge of Informed Consent for Increased Risk Living Donation and Transplantation,”American Journal of Transplantation11, no. 12 (2011): 2569-2574.
11.
Organ Procurement and Transplantation Network, Policy 14.4 “Medical Evaluation Requirements for Living Donors” (2016): 181-187.
12.
Canterbury v. Spence 464 F.2d 772 (D.C. Cir. 1972).
13.
M.Abecassis, M.Adams, and P.Adamset al., “Consensus Statement on the Live Organ Donor,”JAMA, no. 22 284 (2000): 2919-2926. G. M. Danovitch, J. Chapman, A. M. Capron, et al., “Organ Trafficking and Transplant Tourism: The Role of Global Professional Ethical Standards — The 2008 Declaration of Istanbul,” Transplantation 95, no. 11 (2013):1306-1312.
14.
A.Leichtman, M.Abecassis, M.Barr, et al., “Living Kidney Donor Follow-up: State-of-the-Art and Future Directions, Conference Summary and Recommendations,”American Journal of Transplantation11, no. 12 (2011): 2561-2568.
15.
Medicare and Medicaid Services Hospital Conditions of Participation: Requirements for Approval and Re-approval of Transplant Centers to Perform Organ Transplants: Final Rule. Federal Register72, no. 61, (2007): 15197.
16.
Medicare Program; Hospital Conditions of Participation: Requirements for Approval and Re-Approval of Transplant Centers to Perform Organ Transplants; Final Rule. Federal Register. 2007;72 (61)).
17.
D. L.Rudow, “The Living Donor Advocate: A Team Approach to Educate, Evaluate, and Manage Donors Across the Continuum,”Progress in Transplantation19, no. 1 (2009): 64-70.
18.
J.Steel, A.Dunlavy, M.Friday, et al., “A National Survey of Independent Living Donor Advocates: The Need for Practice Guidelines,“American Journal of Transplantation12, no. 8 (2012): 2141-2149; J. L. Steel, A. Dunlavy, M. Friday, et al., “The Development of Practice Guidelines for Independent Living Donor Advocates,” Clinical Transplantation 27, no. 2 (2013): 178-184.
19.
E.Gordon, “Informed Consent for Living Donation: “A Review of Key Empirical Studies, Ethical Challenges and Future Research,”American Journal of Transplantation12, no. 9 (2012): 2273-2280.
20.
C.Thiessen, Y.Kim, R.Formica, M.Bia, and S.Kulkarni, “Written Informed Consent for Living Kidney Donors: Practices and Compliance with CMS and OPTN Requirements,“American Journal of Transplantation13, no. 10 (2013): 2713-2721; J. Rodrigue, M. Pavlakis, G. Danovitch, et al., “Evaluating Living Kidney Donors: Relationship Types, Psychosocial Criteria, and Consent Processes at US Transplant Programs, “ American Journal of Transplantation 7, no. 10: (2007): 2326-2332.
21.
Organ Procurement and Transplantation Network, Policy 14.3, “Informed Consent Requirements” (2016): 177-181.
Organ Procurement and Transplantation Network, Policy 14.3, “Informed Consent Requirements” (2016): 177-181.
24.
A. S.Fink, A. V.Prochazka, and W. G.Hendersonet al., “Enhancement of Surgical Informed Consent by Addition of Repeat Back: A Multicenter, Randomized Controlled Clinical Trial,“Annals of Surgery252, no. 1(2010): 27-36.
25.
R. E.Hays, “Informed Consent of Living Kidney Donors: Pitfalls and Best Practice,”Current Transplantation Reports2, no. 1 (2015): 29-34.
26.
E.Gordon, J.Mullee, N.Beauvais, et al., “Education and Informed Consent About Increased Risk Donor Kidneys: A National Survey of Non-physician Transplant Providers,”Transplant Infectious Disease16, no. 2 (2014): 251-260.
27.
E. J.Gordon, E.Reddy, S.Gil, et al., “Culturally Competent Transplant Program Improves Hispanics' Knowledge and Attitudes About Live Kidney Donation and Transplant,“Progress in Transplantation24, no. 1 (2014): 56-68.
28.
K. L.Lentine, M. A.Schnitzler, H.Xiao, et al., “Racial Variation in Medical Outcomes among Living Kidney Donors,”NEJM363, no. 8 (2010): 724-732.
29.
D. L.Segev, A. D.Muzaale, B. S.Caffo, et al., “Perioperative Mortality and Long-term Survival Following Live Kidney Donation,”JAMA303, no. 10 (2010): 959-966. A. D. Muzaale, A. B. Massie, M.-C. Wang, et al., “Risk of End-Stage Renal Disease Following Live Kidney Donation, “ JAMA 311, no. 6 (2014):579-586.
30.
M. E.Grams, Y.Sang, A. S.Levey, et al., “Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate,”NEJM374, no. 5 (2016) 411-421.
31.
A.Parsa, W. L.Kao, D.Xie, et al., “APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease,“NEJM369, no. 23 (2013): 2183-2196.
32.
P. J.Phelan, P. J.Conlon, and M. A.Sparks, “Genetic Determinants of Renal Transplant Outcome: Where Do We Stand?”Journal of Nephrology27, no. 3 (2014): 247:256.
33.
L. F.Ross and J. R.Thistlethwaite, “Introducing Genetic Tests With Uncertain Implications in Living Donor Kidney Transplantation ApoL1 as a Case Study,”Progress in Transplantation, 3, no. 26 (2016): 203-6.
34.
E.Gordon, “Informed Consent for Living Donation: “A Review of Key Empirical Studies, Ethical Challenges and Future Research,”American Journal of Transplantation12, no. 9 (2012): 2273-2280.
35.
K.Kortram, J. A.Lafranca, J. N.IJzermans, and F. J.Dor, “The Need for a Standardized Informed Consent Procedure in Live Donor Nephrectomy: A Systematic Review,”Transplantation98, no. 11 (2014): 1134-1143.
36.
R. R.Faden and T. L.Beauchamp, A History and Theory of Informed Consent (New York: Oxford University Press, 1986).
37.
Organ Procurement and Transplantation Network, Policy 14.1 “Psychosocial Evaluation Requirements for Living Donors,” January 21, 2016 (2016): 175.
38.
National Organ Transplant Act, (1984), 42 USC § 274e (2015).
39.
OPTN, Policy 14.2 “Independent Living Donor Advocate (ILDA) Requirements,” January 21, 2106 (2016): 176.
40.
R.Hays, D.LaPointe Rudow, M.Dew, S.Taler, H.Spicer, and D.Mandelbrot, “The Independent Living Donor Advocate: A Guidance Document From the American Society of Transplantation's Living Donor Community of Practice (AST LDCOP),”American Journal of Transplantation15, no. 2 (2015): 518-525.
41.
F.Chessa, “Informed Consent for Living Organ Donation,”Living Donor Advocacy (New York: Springer, 2014): at 261-274. I. Sajjad, L. S. Baines, M. Salifu, and R. M. Jindal, “The Dynamics of Recipient-Donor Relationships in Living Kidney Transplantation,” American Journal of Kidney Diseases 50, no. 5 (2007): 834-854; R. Hays and A. J. Matas, “Ethical Review of the Responsibilities of the Patient Advocate in Living Donor Liver Transplant,” Clinical Liver Disease 7, no. 3 (2016): 57-59.
42.
Chessa, supra note 39
43.
H. T.Engelhardt, The Foundations of Bioethics (New York: Oxford University Press, 1996).
44.
C.-M.Lo, “Evaluating the Living Donor: Expansion by Innovation,”Hepatology International10 no. 2 (2016): 242-244.
45.
A. M.Parekh, E. J.Gordon, A. X.Garg, et al., “Living Kidney Donor Informed Consent Practices Vary Between US and Non-US Centers,”Nephrology Dialysis Transplantation23, no. 10 (2008): 3316-3324.
